Delving into the Latest Updates on Shenzhen Xingyin Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Synthetic peptide	1

Top 5 Target	Count

GLP-1R(Glucagon-like peptide 1 receptor)	1

主要研究目的：比较司美格鲁肽注射液和诺和泰®在中国健康受试者中单次皮下注射后的药代动力学（PK），评价两种制剂间PK特征的相似性。次要研究目的：评价司美格鲁肽注射液和诺和泰®在中国健康受试者中单次皮下注射后的安全性。

[Translation]

Primary study objective: To compare the pharmacokinetics (PK) of semaglutide injection and Novota® after a single subcutaneous injection in healthy Chinese subjects, and to evaluate the similarity of PK characteristics between the two preparations. Secondary study objective: To evaluate the safety of semaglutide injection and Novota® after a single subcutaneous injection in healthy Chinese subjects.

Start Date06 Feb 2025

Sponsor / Collaborator

Zhongshan Wanhan Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Shenzhen Xingyin Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Shenzhen Xingyin Pharmaceutical Co. Ltd.

Login to view more data

100 Deals associated with Shenzhen Xingyin Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Shenzhen Xingyin Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data